Q-omics provides the consensus-scored GSC profile across patient tissues and cancer cell-line models. GSC expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GSC is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, GSC RNA expression shows 13,752 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KIRC, and TGCT as cancer lineages where GSC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GSC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GSC survival associations across molecular data types. GSC RNA expression shows survival associations in the most cancer types (27), followed by mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GSC RNA expression–survival associations across cancer types. High GSC expression shows unfavorable associations in ACC, KIRP, CESC, LIHC and UCS, but favorable associations in COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GSC RNA expression.
This table summarizes GSC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for GSC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GSC shows lower tumor expression in THCA and higher tumor expression in KIRC, COAD, UCEC, LUSC and LUAD. The KIRC box plot shows higher GSC RNA expression in tumor versus normal tissue (log2 FC = +0.296, t-test p < 0.001).
This table shows molecular features associated with GSC in patient tissues and cancer cell lines. In patient samples, GSC shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GSC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Lymphoma.
